TuHURA Biosciences (NASDAQ:HURA) Shares Up 2.8% – What’s Next?

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s stock price rose 2.8% during mid-day trading on Thursday . The company traded as high as $2.66 and last traded at $2.59. 397,707 shares changed hands during mid-day trading, a decline of 21% from the average session volume of 500,792 shares. The stock had previously closed at $2.52.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Citizens Jmp started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st. Citigroup assumed coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating for the company. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They set a “buy” rating for the company. Finally, Wall Street Zen lowered shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Price Performance

The stock has a market capitalization of $164.93 million, a P/E ratio of -4.25 and a beta of 0.01. The company has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $1.65.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts forecast that TuHURA Biosciences, Inc. will post -0.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HURA. Virtu Financial LLC bought a new stake in shares of TuHURA Biosciences in the third quarter valued at approximately $26,000. JPMorgan Chase & Co. bought a new position in TuHURA Biosciences in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN grew its stake in TuHURA Biosciences by 109.0% in the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after buying an additional 19,931 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in TuHURA Biosciences in the 4th quarter valued at approximately $30,000. Finally, Invesco Ltd. bought a new stake in TuHURA Biosciences during the 2nd quarter valued at $30,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.